drugset / Trial / NCT01291459
Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients
NaSingle-groupOpen-labelTreatment
Summary
Background and Rationale Raltegravir and Maraviroc, the first in class of 2 new families of antiretroviral drugs have demonstrated a high potency in treatment experienced and naive patients. Both drugs appeared well tolerated with low metabolic toxicity. No data are currently available concerning the combination of these 2 drugs. Hypothesis Maraviroc + Raltegravir should be potent enough to maintain virological efficacy in naive patients infected by CCR5 HIV-1 previously treated for 6 months with a Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination.
Timeline
- Start
- 2011-09
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | — | — |
| Subject | Raltegravir | Other / unclassified | — | — |
| Background | Tenofovir | Small molecule | — | — |
| Background | emtricitabine | Other / unclassified | — | — |